Physician profile
Rajan Mulloth
NPI 1144282518
$29,705.35
in general payments reported to CMS, 2019-2025
61 companies · $5,768 in 2025
The $5,768 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,524 · 2020: $3,266 · 2021: $3,551 · 2022: $3,946 · 2023: $4,557 · 2024: $5,095 · 2025: $5,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,418.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,465.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $3,346.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,355.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,974.68 | 2019-2025 | |
| Amgen INC. | $1,851.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $1,665.22 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,381.32 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Lilly USA, LLC | $1,322.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,257.96 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $871.86 | 2021-2025 | |
| Eisai INC. | $615.34 | 2020-2025 | |
| Astellas Pharma US INC | $613.39 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $529.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $472.53 | 2019-2025 | Xarelto, Spravato |
| Allergan, INC. | $462.10 | 2019-2020 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $459.07 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amarin Pharma, INC. | $458.97 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $398.60 | 2019-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $381.19 | 2022-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $380.11 | 2024-2025 | Zenpep, Vowst |
| Sanofi-Aventis U.S. LLC | $375.98 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $352.74 | 2019-2022 | |
| Lundbeck LLC | $326.16 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $323.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $309.67 | 2019-2023 | Dificid, Gardasil 9, Vaxneuvance |
| Nestle Healthcare Nutrition INC. | $297.28 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.41 | 2019-2024 | Trintellix |
| Radius Health, INC. | $222.16 | 2022-2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $220.73 | 2019-2022 | |
| Abbott Laboratories | $220.27 | 2019-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $212.85 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $205.18 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $192.47 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $192.38 | 2025 | Opsumit, Uptravi |
| Dexcom, INC. | $148.87 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $128.24 | 2023-2025 | Voquezna |
| Esperion Therapeutics, INC. | $127.33 | 2021-2025 | Nexletol |
| Verona Pharma, INC. | $121.67 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $105.80 | 2019-2025 | Licart, Tirosint, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $101.48 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.17 | 2025 | Lifevest |
| Avanir Pharmaceuticals, INC. | $88.79 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $87.35 | 2022 | |
| Almatica Pharma LLC | $81.26 | 2022-2025 | Loreev Xr |
| Ani Pharmaceuticals, INC. | $78.78 | 2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceuticals, INC. | $69.88 | 2021 | |
| Mylan Specialty L.P. | $64.71 | 2019-2023 | Yupelri |
| Neurocrine Biosciences, INC. | $54.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.20 | 2025 | Caplyta |
| Biogen, INC. | $47.02 | 2024-2025 | Leqembi |
| Shield Therapeutics INC | $41.87 | 2023 | Accrufer |
| Regeneron Healthcare Solutions, INC. | $41.48 | 2019 | |
| Globus Medical, INC. | $36.29 | 2025 | Senza |
| Insmed, INC. | $36.20 | 2025 | Arikayce |
| Idorsia Pharmaceuticals US INC | $34.44 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $32.47 | 2024 | Keveyis |
| Abiomed | $22.96 | 2025 | |
| Shire North American Group INC | $15.49 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.36 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $14.07 | 2019 | |
| Genentech USA, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Mulloth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.